27567841|t|Butyrylcholinesterase K and Apolipoprotein E-e4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
27567841|a|BACKGROUND: Genetic heterogeneity in amnestic mild cognitively impaired (aMCI) subjects could lead to variations in progression rates and response to cholinomimetic agents. Together with the apolipoprotein E4 (APOE-e4) gene, butyrylcholinesterase (BCHE) has become recently one of the few Alzheimer's disease (AD) susceptibility genes with distinct pharmacogenomic properties. OBJECTIVE: To validate candidate genes (APOE/BCHE) which display associations with age of onset of AD and donepezil efficacy in aMCI subjects. METHODS: Using the Petersen et al. (2005) study on vitamin E and donepezil efficacy in aMCI, we contrasted the effects of BCHE and APOE variants on donepezil drug response using the Alzheimer's Disease Assessment Score-Cognition (ADAS-Cog) scale. Independently, we assessed the effects of APOE/BCHE genotypes on age of onset and cortical choline acetyltransferase activity in autopsy-confirmed AD and age-matched control subjects. RESULTS: Statistical analyses revealed a significant earlier age of onset in AD for APOE-e4, BCHE-K*, and APOE-e4/BCHE-K* carriers. Among the carriers of APOE-e4 and BCHE-K*, the benefit of donepezil was evident at the end of the three-year follow-up. The responder's pharmacogenomic profile is consistent with reduced brain cholinergic activity measured in APOE-e4 and BCHE-K* positive subjects. CONCLUSIONS: APOE-e4 and BCHE-K* positive subjects display an earlier age of onset of AD, an accelerated cognitive decline and a greater cognitive benefits to donepezil therapy. These results clearly emphasize the necessity of monitoring potential pharmacogenomic effects in this population of subjects, and suggest enrichment strategies for secondary prevention trials involving prodromal AD subjects.
27567841	75	94	Alzheimer's Disease	Disease	MESH:D000544
27567841	107	124	Cognitive Decline	Disease	MESH:D003072
27567841	139	148	Donepezil	Chemical	MESH:D000077265
27567841	166	186	Cognitively Impaired	Disease	MESH:D003072
27567841	234	268	amnestic mild cognitively impaired	Disease	MESH:D060825
27567841	270	274	aMCI	Disease	MESH:D060825
27567841	388	405	apolipoprotein E4	Gene	348
27567841	407	414	APOE-e4	Gene	348
27567841	422	443	butyrylcholinesterase	Gene	590
27567841	445	449	BCHE	Gene	590
27567841	486	505	Alzheimer's disease	Disease	MESH:D000544
27567841	507	509	AD	Disease	MESH:D000544
27567841	614	618	APOE	Gene	348
27567841	619	623	BCHE	Gene	590
27567841	673	675	AD	Disease	MESH:D000544
27567841	680	689	donepezil	Chemical	MESH:D000077265
27567841	702	706	aMCI	Disease	MESH:D060825
27567841	768	777	vitamin E	Chemical	MESH:D014810
27567841	782	791	donepezil	Chemical	MESH:D000077265
27567841	804	808	aMCI	Disease	MESH:D060825
27567841	839	843	BCHE	Gene	590
27567841	848	852	APOE	Gene	348
27567841	865	874	donepezil	Chemical	MESH:D000077265
27567841	899	918	Alzheimer's Disease	Disease	MESH:D000544
27567841	1006	1010	APOE	Gene	348
27567841	1011	1015	BCHE	Gene	590
27567841	1111	1113	AD	Disease	MESH:D000544
27567841	1225	1227	AD	Disease	MESH:D000544
27567841	1232	1239	APOE-e4	Gene	348
27567841	1254	1261	APOE-e4	Gene	348
27567841	1302	1309	APOE-e4	Gene	348
27567841	1338	1347	donepezil	Chemical	MESH:D000077265
27567841	1506	1513	APOE-e4	Gene	348
27567841	1558	1565	APOE-e4	Gene	348
27567841	1631	1633	AD	Disease	MESH:D000544
27567841	1650	1667	cognitive decline	Disease	MESH:D003072
27567841	1704	1713	donepezil	Chemical	MESH:D000077265
27567841	1935	1937	AD	Disease	MESH:D000544
27567841	Negative_Correlation	MESH:D000077265	MESH:D003072
27567841	Negative_Correlation	MESH:D014810	MESH:D060825
27567841	Negative_Correlation	MESH:D000077265	MESH:D060825
27567841	Association	MESH:D000544	590
27567841	Association	MESH:D000544	348
27567841	Association	MESH:D000077265	348
27567841	Negative_Correlation	MESH:D000077265	MESH:D000544
27567841	Association	MESH:D000077265	590

